Clinical Trials Now Enrolling
RIBOCICLIB IN PREOPERATIVE GLIOMA AND MENINGIOMA PATIENTS
A Phase 0/2 Study of Ribociclib in Preoperative Rb-Positive Recurrent High-Grade Glioma and Meningioma Patients Scheduled for Resection
Am I eligible?
Visit ClinicalTrials.gov or use NCT identifier NCT02933736 to view inclusion criteria and additional study details.
RIBOCICLIB AND EVEROLIMUS FOR GLIOBLASTOMA PATIENTS
A Phase 0/2 Study of Ribociclib in Combination With Everolimus in Preoperative Rb-Intact Recurrent High-Grade Glioma Patients Scheduled for Resection
Am I eligible?
Visit ClinicalTrials.gov or use NCT identifier NCT03834740 to view inclusion criteria and additional study details.
Ceritinib in Preoperative Glioblastoma and Metastatic Brain Tumors
A Phase 0 Study of Ceritinib in Preoperative Glioblastoma Multiforme and CNS Metastasis
This list was last updated 11/19/2019
Am I eligible?
Visit ClinicalTrials.gov or use NCT identifier NCT02605746 to view inclusion criteria and additional study details.
Get a Second Opinion>
Trial screening requests are provided at no cost and the Ivy Brain Tumor Center covers all medical costs associated with study participation outside of routine care.
Within two business days of a trial screening request, our team assesses a patient’s suitability for our clinical trials program, as well as provides additional support to the physicians managing these cases. Patients enrolled in our studies are not required to transfer their care to our center, as our philosophy is to partner with, not replace, their treatment team.
NEW DIAGNOSis?
Ivy Phase 0 clinical trials are currently available for patients whose tumors have recurred and require surgery. If you are a newly-diagnosed brain tumor patient, please feel free to contact us for additional information on current standard-of-care treatments. In the event that your tumor does recur, we will have options. Talk to an Ivy Navigator today to discuss establishing a proactive treatment plan.
